Thus, this study demonstrates that NQO1 plays a key role in HIF-1α stabilization, and a dual treatment with dicoumarol and sorafenib can significatively increase sorafenib sensitivity in ovarian cancer cells [52]. This evidence concerns the gene HIF1A and ovarian carcinoma.